Faculty
Bruce Roth.jpg

Bruce J. Roth, MD

Professor
Department of Medicine
Oncology Division
Medical Oncology

Research Interests

  • Prostate cancer
  • Urothelial carcinomas
  • Testicular cancer
  • Cancers of the kidney

Contact

  • 314-362-5817 (tel)
  • 314-362-7086 (fax)
  • Division of Oncology
    Campus Box 8056
    Washington University School of Medicine
    660 South Euclid Avenue
    St. Louis, MO 63110

Articles

  • Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm
    Tandstad T, Kollmannsberger CK, Roth BJ, Jeldres C, Gillessen S, Fizazi K, Daneshmand S, Lowrance WT, Hanna NH, Albany C, Foster R, Cedermark GC, Feldman DR, Powles T, Lewis MA, Grimison PS, Bank D, Porter C, Albers P, De Santis M, Srinivas S, Bosl GJ, Nichols CR
    J Clin Oncol 2017 Nov 1;35(31):3525-3528
  • Cabozantinib Versus Everolimus in Advanced Renal Cell Carcinoma (METEOR): Final Results From a Randomised, Open-Label, Phase 3 Trial
    Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DY, Schmidinger M, Agarwal N, Sternberg CN, McDermott DF, Aftab DT, Hessel C, Scheffold C, Schwab G, Hutson TE, Pal S, Motzer RJ
    METEOR investigators

    Lancet Oncol 2016 Jul;17(7):917-27
  • Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2015
    Lowrance WT, Roth BJ, Kirkby E, Murad MH, Cookson MS
    J Urol 2016 May;195(5):1444-1452
  • Cabozantinib Versus Everolimus in Advanced Renal-Cell Carcinoma
    Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Geczi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ
    METEOR investigators

    N Engl J Med 2015 Nov 5;373(19):1814-1823
  • Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
    Patel JD, Krilov L, Adams S, Aghajanian C, Basch E, Brose MS, Carroll WL, de Lima M, Gilbert MR, Kris MG, Marshall JL, Masters GA, O'Day SJ, Polite B, Schwartz GK, Sharma S, Thompson I, Vogelzang NJ, Roth BJ
    J Clin Oncol 2014 Jan 10;32(2):129-60
  • How to Diagnose, Classify and Monitor Prostate Cancer
    Mohammed A, Roth BJ
    J OncoPathology 2013;1(3):43-9
  • Active Surveillance Is the Preferred Approach to Clinical Stage I Testicular Cancer
    Nichols CR, Roth B, Albers P, Einhorn LH, Foster R, Daneshmand S, Jewett M, Warde P, Sweeney CJ, Beard C, Powles T, Tyldesley S, So A, Porter C, Olgac S, Fizazi K, Hayes-Lattin B, Grimison P, Toner G, Cathomas R, Bokemeyer C, Kollmannsberger C
    J Clin Oncol 2013 Oct 1;31(28):3490-3
  • Castration-Resistant Prostate Cancer: AUA Guideline
    Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, Lin DW, Lowrance WT, Murad MH, Oh WK, Penson DF, Kibel AS
    J Urol 2013 Aug;190(2):429-38
  • Optimizing Outcomes in Testicular Cancer by Simply Following the Rules
    Nichols CR, Roth BJ, Kollmannsberger C
    Proc 2013 ASCO Genitourinary Oncology Symposium
  • Clinical Cancer Advances 2012: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
    Roth BJ, Krilov L, Adams S, Aghajanian CA, Bach P, Braiteh F, Brose MS, Ellis LM, Erba H, George DJ, Gilbert MR, Jacobson JO, Larsen EC, Lichtman SM, Partridge AH, Patel JD, Quinn DI, Robison LL, von Roenn JH, Samlowski W, Schwartz GK, Vogelzang NJ
    J Clin Oncol 2013 Jan 1;31(1):131-61
  • Prostate-Specific Antigen Test for Prostate Cancer Screening: American Society of Clinical Oncology Provisional Clinical Opinion
    Nam RK, Oliver TK, Vickers AJ, Thompson I, Kantoff PW, Parnes HL, Loblaw A, Roth BJ, Williams J, Temin S, Basch E
    J Oncol Pract 2012 Sep;8(5):315-7
  • Screening for Prostate Cancer With Prostate-Specific Antigen Testing: American Society of Clinical Oncology Provisional Clinical Opinion
    Basch E, Oliver TK, Vickers A, Thompson I, Kantoff P, Parnes H, Loblaw DA, Roth B, Williams J, Nam RK
    J Clin Oncol 2012 Aug 20;30(24):3020-5
  • Classical Clinical Trial Design in Testicular Cancer: Time to Move On
    Nichols CR, Roth B, Kollmannsberger C
    J Clin Oncol 2012 Mar 10;30(8):769-71
  • Clinical Cancer Advances 2011: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
    Vogelzang NJ, Benowitz SI, Adams S, Aghajanian C, Chang SM, Dreyer ZE, Janne PA, Ko AH, Masters GA, Odenike O, Patel JD, Roth BJ, Samlowski WE, Seidman AD, Tap WD, Temel JS, Von Roenn JH, Kris MG
    J Clin Oncol 2012 Jan 1;30(1):88-109
  • Comparative Effectiveness of Cisplatin-Based and Carboplatin-Based Chemotherapy for Treatment of Advanced Urothelial Carcinoma
    Galsky MD, Chen GJ, Oh WK, Bellmunt J, Roth BJ, Petrioli R, Dogliotti L, Dreicer R, Sonpavde G
    Ann Oncol 2012 Feb;23(2):406-10
  • NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer
    Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, Enke CA, George D, Horwitz EM, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Macvicar G, Plimack ER, Pow-Sang JM, Roach M 3rd, Rohren E, Roth BJ, Shrieve DC, Smith MR, Srinivas S, Twardowski P, Walsh PC
    J Natl Compr Canc Netw 2010 Feb;8(2):162-200
  • A Randomized Phase II Trial of Mitoxantrone, Estramustine and Vinorelbine or Bcl-2 Modulation With 13-Cis Retinoic Acid, Interferon and Paclitaxel in Patients With Metastatic Castrate-Resistant Prostate Cancer: ECOG 3899
    DiPaola RS, Chen YH, Stein M, Vaughn D, Patrick-Miller L, Carducci M, Roth B, White E, Wilding G
    J Transl Med 2010 Feb 24;8:20
  • Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1
    Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, Rodon J, Murphy B, Roth B, McCaffery I, Gorski KS, Kaiser B, Zhu M, Deng H, Friberg G, Puzanov I
    J Clin Oncol 2009 Dec 1;27(34):5800-7
  • Phase 2 Trial of Sorafenib in Patients With Advanced Urothelial Cancer: A Trial of the Eastern Cooperative Oncology Group
    Dreicer R, Li H, Stein M, DiPaola R, Eleff M, Roth BJ, Wilding G
    Cancer 2009 Sep 15;115(18):4090-5
  • A Phase I Trial of Irinotecan Alternating With Epirubicin in Patients With Advanced Malignancies
    Goff LW, Rothenberg ML, Lockhart AC, Roth BJ, VerMeulen WL, Chan E, Berlin JD
    Am J Clin Oncol 2008 Oct;31(5):413-6
  • Prostate Cancer Serum Biomarker Discovery Through Proteomic Analysis of Alpha-2 Macroglobulin Protein Complexes
    Burgess EF, Ham AJ, Tabb DL, Billheimer D, Roth BJ, Chang SS, Cookson MS, Hinton TJ, Cheek KL, Hill S, Pietenpol JA
    Proteomics Clin Appl 2008 Jul 30;2(9):1223-1233
  • Phase 2 Trial of Pemetrexed Disodium and Gemcitabine in Advanced Urothelial Cancer (E4802): A Trial of the Eastern Cooperative Oncology Group
    Dreicer R, Li H, Cooney MM, Wilding G, Roth BJ
    Cancer 2008 Jun 15;112(12):2671-5
  • Managing the Side Effects of Androgen-Deprivation Therapy
    Roth BJ
    J Supp Oncol 2007;5(2):87-88
  • Phase 2 Trial of Epothilone B Analog BMS-247550 (Ixabepilone) in Advanced Carcinoma of the Urothelium (E3800): A Trial of the Eastern Cooperative Oncology Group
    Dreicer R, Li S, Manola J, Haas NB, Roth BJ, Wilding G
    Cancer 2007 Aug 15;110(4):759-63
  • Phase I Dose Escalation and Pharmacokinetic Study of AZD2171, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase, in Patients With Hormone Refractory Prostate Cancer (HRPC)
    Ryan CJ, Stadler WM, Roth B, Hutcheon D, Conry S, Puchalski T, Morris C, Small EJ
    Invest New Drugs 2007 Oct;25(5):445-51
  • Adjuvant Weekly Docetaxel for Patients With High Risk Prostate Cancer After Radical Prostatectomy: A Multi-Institutional Pilot Study
    Kibel AS, Rosenbaum E, Kattan MW, Picus J, Dreicer R, Klein EA, Chatta GS, Nelson JB, DiPaola RS, Roth BJ, Cookson MS, Wilding G, Jarrard DF, Beer TM, Ryan CW, Petrylak DP, Benson MC, Partin AW, Garrett-Mayer E, Eisenberger MA
    J Urol 2007 May;177(5):1777-81
  • Phase I/II Study of Bortezomib Plus Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer
    Dreicer R, Petrylak D, Agus D, Roth B
    Clin Cancer Res 2007 Feb 15;13(4):1208-15
  • Sperm Banking: Use and Outcomes in Patients Treated for Testicular Cancer
    Girasole CR, Cookson MS, Smith JA Jr, Ivey BS, Roth BJ, Chang SS
    BJU Int 2007 Jan;99(1):33-6
  • Management of Recurrent Testicular Germ Cell Tumors
    Sonpavde G, Hutson TE, Roth BJ
    Oncologist 2007 Jan;12(1):51-61
  • Phase II Study of Pemetrexed for Second-Line Treatment of Transitional Cell Cancer of the Urothelium
    Sweeney CJ, Roth BJ, Kabbinavar FF, Vaughn DJ, Arning M, Curiel RE, Obasaju CK, Wang Y, Nicol SJ, Kaufman DS
    J Clin Oncol 2006 Jul 20;24(21):3451-7
  • Phase II Study of Carboxyamidotriazole in Patients With Advanced Renal Cell Carcinoma Refractory to Immunotherapy: E4896, an Eastern Cooperative Oncology Group Study
    Dutcher JP, Leon L, Manola J, Friedland DM, Roth B, Wilding G
    Cancer 2005 Dec 1;104(11):2392-9
  • Plenary I
    Roth BJ
    American Society of Clinical Oncology Annual Meeting Summaries 2005:221-225
  • Performance-Enhancing Supplement Use in Patients With Testicular Cancer
    Chang SS, Ivey B, Smith JA Jr, Roth BJ, Cookson MS
    Urology 2005 Aug;66(2):242-5
  • Changing Perspectives of the Role of Chemotherapy in Advanced Prostate Cancer
    Burgess EF, Roth BJ
    Urol Clin North Am 2006 May;33(2):227-36, vii
  • A Reappraisal of Chemotherapy in the Treatment of Prostate Cancer
    Vogelzang NJ, Kantoff PW, Pienta KJ, Roth BJ, Sweeney CJ
    Monograph, AAF-MED 2005:1-26
  • Prostate Cancer Chemotherapy: Emerging From the Shadows
    Roth BJ
    J Clin Oncol 2005 May 20;23(15):3302-3
  • A Phase I Dose-Escalation and Pharmacokinetic Study of Brostallicin (PNU-166196A), a Novel DNA Minor Groove Binder, in Adult Patients With Advanced Solid Tumors
    Lockhart AC, Howard M, Hande KR, Roth BJ, Berlin JD, Vreeland F, Campbell A, Fontana E, Fiorentini F, Fowst C, Paty VA, Lankford O, Rothenberg ML
    Clin Cancer Res 2004 Jan 15;10(2):468-75
  • Phase III Trial of Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Versus Carboplatin and Paclitaxel in Patients With Advanced Carcinoma of the Urothelium
    Dreicer R, Manola J, Roth BJ, See WA, Kuross S, Edelman MJ, Hudes GR, Wilding G
    Cancer 2004 Apr 15;100(8):1639-45
  • Phase II Trial of Gemcitabine and Docetaxel in Patients With Advanced Carcinoma of the Urothelium: A Trial of the Eastern Cooperative Oncology Group
    Dreicer R, Manola J, Schneider DJ, Schwerkoske JF, George CS, Roth BJ, Wilding G
    Cancer 2003 Jun 1;97(11):2743-7
  • Beneficial Impact of a Clinical Care Pathway in Patients With Testicular Cancer Undergoing Retroperitoneal Lymph Node Dissection
    Chang SS, Smith JA Jr, Girasole C, Baumgartner RG, Roth BJ, Cookson MS
    J Urol 2002 Jul;168(1):87-92
  • Piritrexim in Advanced, Refractory Carcinoma of the Urothelium (E3896): A Phase II Trial of the Eastern Cooperative Oncology Group
    Roth BJ, Manola J, Dreicer R, Graham D, Wilding G
    Invest New Drugs 2002 Nov;20(4):425-9
  • Prostate Cancer: Treating Localized Disease
    Roth B
    Federal Practitioner 2002;19 (Suppl):9-14
  • The Role of Chemotherapy in Metastatic Disease
    Roth B
    Advances in Bladder Cancer 2002;1(1):3-10
  • Chemotherapy in the Prostate Cancer Patient With Asymptomatic Serologic Progression: Premature or Overdue?
    Roth B
    American Society of Clinical Oncology Educational Booklet 2002:540-547
  • Overview of Advanced Urothelial Cancer Trials of the Eastern Cooperative Oncology Group
    Dreicer R, Roth B, Wilding G
    Cancer 2003 Apr 15;97(8 Suppl):2109-14
  • Chemotherapy for Genitourinary Malignancies: A Few Victories, More Promises, and a Lot of Unfinished Business
    Roth BJ
    Semin Urol Oncol 2001 Aug;19(3):155-6
  • Treatment of Clinical Stage I Germ Cell Tumors
    Chang SS, Roth B
    Urology 2002 Feb;59(2):173-9
  • Systemic Chemotherapy for Urothelial Transitional Cell Carcinoma: An Overview of Toxicity
    Moulder SL, Roth BJ
    Semin Urol Oncol 2001 Aug;19(3):194-201
  • Vinblastine Versus Vinblastine Plus Oral Estramustine Phosphate for Patients With Hormone-Refractory Prostate Cancer: A Hoosier Oncology Group and Fox Chase Network Phase III Trial
    Hudes G, Einhorn L, Ross E, Balsham A, Loehrer P, Ramsey H, Sprandio J, Entmacher M, Dugan W, Ansari R, Monaco F, Hanna M, Roth B
    Classic Papers and Current Comments 2001;6(2):318-325
  • Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen Independent Prostate Cancer: Recommendations From the PSA Working Group
    Bubley G, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak D, Reed E, Roth B, Sartor O, Scher H, Simons J, Small E, Smith M, Trump D, Vollmer R, Wilding G
    Classic Papers and Current Comments 2001;6(2):311-317
  • Phase I Trial of Weekly Paclitaxel Plus Oral Estramustine Phosphate in Patients With Hormone-Refractory Prostate Cancer
    Haas N, Roth B, Garay C, Yeslow G, Entmacher M, Weinstein A, Rogatko A, Babb J, Minnitti C, Flinker D, Gillon T, Hudes G
    Urology 2001 Jul;58(1):59-64
  • Phase I Trial of Paclitaxel and Etoposide for Recurrent Ovarian Carcinoma: A Gynecologic Oncology Group Study
    Fleming GF, Roth BJ, Baker SD, Sutton GP, Look KY, Muggia FM, Fracasso PM, McGuire WP 3rd
    Am J Clin Oncol 2000 Dec;23(6):609-13
  • Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
    Roth BJ
    American Society of Clinical Oncology Education Booklet 2001:376-381
  • Abnormal Mammogram as the Presenting Sign of Renal Cell Carcinoma
    Grossklaus DJ, Holzbeierlein JM, Roth BJ, Smith JA Jr
    J Urol 2000 Apr;163(4):1239-40
  • Phase II Study of Cisplatin and Paclitaxel in Advanced Carcinoma of the Urothelium: An Eastern Cooperative Oncology Group Study
    Dreicer R, Manola J, Roth BJ, Cohen MB, Hatfield AK, Wilding G
    J Clin Oncol 2000 Mar;18(5):1058-61
  • Vinblastine Versus Vinblastine Plus Oral Estramustine Phosphate for Patients With Hormone-Refractory Prostate Cancer: A Hoosier Oncology Group and Fox Chase Network Phase III Trial
    Hudes G, Einhorn L, Ross E, Balsham A, Loehrer P, Ramsey H, Sprandio J, Entmacher M, Dugan W, Ansari R, Monaco F, Hanna M, Roth B
    J Clin Oncol 1999 Oct;17(10):3160-6
  • Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group
    Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G, et al.
    J Clin Oncol 1999 Nov;17(11):3461-7
  • Androgen-Independent Prostate Cancer: Not So Chemorefractory After All
    Roth BJ
    Semin Oncol 1999 Dec;26(6 Suppl 18):43-50
  • A Phase II Study of Paclitaxel and Ifosfamide for Patients With Advanced Refractory Carcinoma of the Urothelium
    Sweeney CJ, Williams SD, Finch DE, Bihrle R, Foster RS, Collins M, Fox S, Roth BJ
    Cancer 1999 Aug 1;86(3):514-8
  • Bilateral Testicular Tumors: Management and Outcome in 21 Patients
    Coogan CL, Foster RS, Simmons GR, Tognoni PG, Roth BJ, Donohue JP
    Cancer 1998 Aug 1;83(3):547-52
  • A Man With Voiding Difficulties and Back Pain
    Koch MO, Roth BJ
    American Urological Association Patient Management Problems Vol 4, 1998
  • Chemotherapy in Hormone-Refractory Prostate Cancer
    Roth BJ
    Family Urology 1998;3(2):8-10
  • Medical Management of Bladder Cancer: Clinical Advances for Cancer Care
    Roth BJ
    Federal Practitioner 1998;15:6S (Suppl):13-16
  • Postchemotherapy Retroperitoneal Lymph Node Dissection Is Effective Therapy in Selected Patients With Elevated Tumor Markers After Primary Chemotherapy Alone
    Coogan CL, Foster RS, Rowland RG, Bihrle R, Smith ER Jr, Einhorn LH, Roth BJ, Donohue JP
    Urology 1997 Dec;50(6):957-62
  • Metastatic Bladder Cancer: Advances in Treatment
    Stadler WM, Kuzel TM, Raghavan D, Levine E, Vogelzang NJ, Roth B, Dorr FA
    Eur J Cancer 1997 Jan;33 Suppl 1:S23-6
  • Significant Activity of Paclitaxel in Advanced Transitional Cell Carcinoma of the Urothelium: A Phase II Trial of the Eastern Cooperative Oncology Group
    Roth BJ, Dreicer R, Einhorn LH, Neuberg D, Johnson DH, Smith JL, Hudes GR, Schultz SM, Loehrer PJ
    Classic Papers and Current Comments 1998;3
  • Effects of Doxycycline on Human Prostate Cancer Cells in Vitro
    Fife RS, Sledge GW Jr, Roth BJ, Proctor C
    Cancer Lett 1998 May 15;127(1-2):37-41
  • A Phase II Trial of Paclitaxel in Refractory Germ Cell Tumors
    Sandler AB, Cristou A, Fox S, Williams SD, Nichols CR, Turns M, Roth BJ
    Cancer 1998 Apr 1;82(7):1381-6
  • Randomized Study of Cyclophosphamide, Doxorubicin, and Vincristine Versus Etoposide and Cisplatin Versus Alternation of These Two Regimens in Extensive Small-Cell Lung Cancer: A Phase III Trial of the Southeastern Cancer Study Group
    Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, Crawford J, Randolph JA, Goodlow JL, Broun GO, Omura GA, Greco FA
    Classic Papers and Current Comments 1997;2(1):72-82
  • Clinical Stage I Nonseminoma: Surgery Versus Surveillance
    Foster RS, Roth BJ
    Semin Oncol 1998 Apr;25(2):145-53
  • Phase II Study of Single-Agent Gemcitabine in Previously Untreated Patients With Metastatic Urothelial Cancer
    Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA
    J Clin Oncol 1997 Nov;15(11):3394-8
  • Vinblastine, Ifosfamide, and Gallium Nitrate--An Active New Regimen in Patients With Advanced Carcinoma of the Urothelium. A Phase II Trial of the Eastern Cooperative Oncology Group (E5892)
    Dreicer R, Propert KJ, Roth BJ, Einhorn LH, Loehrer PJ
    Cancer 1997 Jan 1;79(1):110-4
  • Highlights of Abstracts on Hormone-Refractory Prostate Cancer Presented at the 1996 Annual Meeting of the American Society of Clinical Oncology
    Roth BJ
    Semin Oncol 1996 Dec;23(6 Suppl 14):6-7
  • Neoadjuvant Hormonal Therapy in Localized Prostate Cancer
    Roth BJ
    New Developments in Prostate Cancer Treatment 1997;2(1):17-23
  • New Therapeutic Agents for Hormone-Refractory Prostate Cancer
    Roth BJ
    Semin Oncol 1996 Dec;23(6 Suppl 14):49-55
  • Ifosfamide in the Treatment of Bladder Cancer
    Roth BJ
    Semin Oncol 1996 Jun;23(3 Suppl 6):50-5
  • The Role of Ifosfamide in the Treatment of Testicular and Urothelial Malignancies
    Roth BJ
    Semin Oncol 1996 Jun;23(3 Suppl 7):19-27
  • Cost- And Risk-Benefit Considerations in the Management of Clinical Stage I Nonseminomatous Testicular Tumors
    Baniel J, Roth BJ, Foster RS, Donohue JP
    Ann Surg Oncol 1996 Jan;3(1):86-93
  • Chemotherapy for Advanced Bladder Cancer
    Roth BJ
    Semin Oncol 1996 Oct;23(5):633-44
  • The Role of Paclitaxel in the Therapy of Bladder Cancer
    Roth BJ
    Semin Oncol 1995 Oct;22(5 Suppl 12):33-40
  • Cost and Risk Benefit in the Management of Clinical Stage II Nonseminomatous Testicular Tumors
    Baniel J, Roth BJ, Foster RS, Donohue JP
    Cancer 1995 Jun 15;75(12):2897-903
  • Response of Bidimensionally Measurable Metastases to Flutamide Withdrawal in a Patient With Advanced Prostate Cancer
    Warren GP, Roth BJ
    Indiana Med 1996 May-Jun;89(3):274-7
  • Advanced Bladder Cancer: The Need to Identify New Agents in the Post-M-VAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) World
    Roth BJ, Bajorin DF
    J Urol 1995 Mar;153(3 Pt 2):894-900
  • Combination Chemotherapy in Advanced Prostate Cancer: A Silk Purse?
    Roth BJ
    J Clin Oncol 1994 Oct;12(10):2001-2
  • Salvage Chemotherapy for Recurrent Germ Cell Cancer
    Nichols CR, Roth BJ, Loehrer PJ, Williams SD, Einhorn LH
    Semin Oncol 1994 Oct;21(5 Suppl 12):102-8
  • Phase II Trial of Vinblastine, Ifosfamide, and Gallium Combination Chemotherapy in Metastatic Urothelial Carcinoma
    Einhorn LH, Roth BJ, Ansari R, Dreicer R, Gonin R, Loehrer PJ
    J Clin Oncol 1994 Nov;12(11):2271-6
  • Significant Activity of Paclitaxel in Advanced Transitional-Cell Carcinoma of the Urothelium: A Phase II Trial of the Eastern Cooperative Oncology Group
    Roth BJ, Dreicer R, Einhorn LH, Neuberg D, Johnson DH, Smith JL, Hudes GR, Schultz SM, Loehrer PJ
    J Clin Oncol 1994 Nov;12(11):2264-70
  • Palliative Chemotherapy in Advanced Bladder Cancer
    Roth BJ
    Semin Oncol 1995 Apr;22(2 Suppl 3):10-5
  • Preliminary Experience With Paclitaxel in Advanced Bladder Cancer
    Roth BJ
    Semin Oncol 1995 Jun;22(3 Suppl 6):1-5
  • Incidence of Neutropenic Fever in Patients Treated With Standard-Dose Combination Chemotherapy for Small-Cell Lung Cancer and the Cost Impact of Treatment With Granulocyte Colony-Stimulating Factor
    Nichols CR, Fox EP, Roth BJ, Williams SD, Loehrer PJ, Einhorn LH
    J Clin Oncol 1994 Jun;12(6):1245-50
  • Early Salvage Therapy for Germ Cell Cancer Using High Dose Chemotherapy With Autologous Bone Marrow Support
    Broun ER, Nichols CR, Turns M, Williams SD, Loehrer PJ, Roth BJ, Lazarus HM, Einhorn LH
    Cancer 1994 Mar 15;73(6):1716-20
  • Prognostic Factors in Stage III Testicular Cancer
    Roth BJ
    Aktuelle Onkologie 1993;78:1165-176
  • Taxol in Advanced, Hormone-Refractory Carcinoma of the Prostate. A Phase II Trial of the Eastern Cooperative Oncology Group
    Roth BJ, Yeap BY, Wilding G, Kasimis B, McLeod D, Loehrer PJ
    Cancer 1993 Oct 15;72(8):2457-60
  • Chemotherapy for Testicular Cancer: 1994
    Roth BJ, Nichols CR
    American Urological Association Update Series 1994;13(22):174-180
  • 5-Azacytidine (NSC 102816) in Refractory Germ Cell Tumors. A Phase II Trial of the Eastern Cooperative Oncology Group
    Roth BJ, Elson P, Sledge GW Jr, Einhorn LH, Trump DL
    Invest New Drugs 1993 May-Aug;11(2-3):201-2
  • Dose Intensity in Germ Cell Cancer: Continued Lessons From a Model Neoplasm
    Nichols CR, Roth BJ, Broun ER, Loehrer PJ, Williams SD, Einhorn LH
    Eur Urol 1993;23(1):231-8; discussion 239
  • Surgical Salvage of Chemorefractory Germ Cell Tumors
    Murphy BR, Breeden ES, Donohue JP, Messemer J, Walsh W, Roth BJ, Einhorn LH
    J Clin Oncol 1993 Feb;11(2):324-9
  • Comparison of N-Acetylcysteine and Mesna as Uroprotectors With Ifosfamide Combination Chemotherapy in Refractory Germ Cell Tumors
    Munshi NC, Loehrer PJ Sr, Williams SD, Langefeld C, Sledge G, Nichols CR, Roth BJ, Neuman A, Walsh WB, Einhorn LH
    Invest New Drugs 1992 Aug;10(3):159-63
  • No Evidence of Acute Cardiovascular Complications of Chemotherapy for Testicular Cancer: An Analysis of the Testicular Cancer Intergroup Study
    Nichols CR, Roth BJ, Williams SD, Gill I, Muggia FM, Stablein DM, Weiss RB, Einhorn LH
    J Clin Oncol 1992 May;10(5):760-5
  • Randomized Study of Cyclophosphamide, Doxorubicin, and Vincristine Versus Etoposide and Cisplatin Versus Alternation of These Two Regimens in Extensive Small-Cell Lung Cancer: A Phase III Trial of the Southeastern Cancer Study Group
    Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, Crawford J, Randolph JA, Goodlow JL, Broun GO, et al.
    J Clin Oncol 1992 Feb;10(2):282-91
  • Testicular Cancer in the 90s: Victory ... And a New Call to Arms
    Roth BJ, Nichols CR
    Semin Oncol 1992 Apr;19(2):117-8
  • Chemotherapy of Testis Cancer: A Review
    Williams SD, Roth BJ
    Int J Radiat Oncol Biol Phys 1992;22(1):213-7
  • Binding of Insulin-Like Growth Factors to Tera-2 Human Embryonal Carcinoma Cells During Differentiation
    Fleck JF, Sledge GW Jr, Benenati SV, Frolik CA, Roth BJ, Hirsch KS
    Cancer Res 1991 Aug 15;51(16):4395-401
  • Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Metastatic Breast Cancer. A Phase II Trial of the Hoosier Oncology Group
    Roth BJ, Sledge GW Jr, Williams SD, Meyer SC, Ansari R, Fisher WB
    Cancer 1991 Jul 15;68(2):248-52
  • Managing Testicular Cancer
    Nichols CR, Roth BJ, Einhorn LH
    Contemporary Oncology 1991 May/June:13-30
  • Oral Etoposide: A Novel Chemotherapeutic Agent
    Roth BJ
    Proceedings of the Nippon Kayaku Lastet Conference, Tokyo, Japan, July 1990, pp 50-66, 1991
  • Hematologic Neoplasia Associated With Primary Mediastinal Germ-Cell Tumors
    Nichols CR, Roth BJ, Heerema N, Griep J, Tricot G
    N Engl J Med 1990 May 17;322(20):1425-9
  • Long-Term Side Effects After Treatment of Testicular Cancer
    Fossa SD, Kreuser ED, Roth BJ, Raghavan D
    Prog Clin Biol Res 1990;357:321-330
  • Complications of Urologic Chemotherapy
    Roth B, Williams S
    American Urological Association Update Series 1990;9(4):26-32
  • Management of Patients With Non-Seminomatous Germ Cell Tumours Stage I
    Rorth M, Cullen MH, Horwich A, Roth BJ
    Prog Clin Biol Res 1990;357:295-303
  • Growth Factors and Differentiation: A New Concept in the Evaluation of Germ Cell Tumor Biological Behavior
    Fleck JF, Roth BJ, Sledge GW
    Revista de Hospital de Clinicas de Porto Alegre (Brazil) 1989;9:105-118
  • Disseminated Testis Cancer: Approaching Its Next Decade
    Williams SD, Loehrer PJ, Nichols CR, Roth BJ, Einhorn LH
    Adv Oncol 1989;5:27-29
  • Disseminated Testicular Cancer: Current Chemotherapy Strategies
    Williams SD, Loehrer PJ, Nichols CR, Roth BJ, Einhorn LH
    Semin Oncol 1989 Aug;16(4 Suppl 6):105-9
  • Cisplatin in the Management of Breast Cancer
    Sledge GW Jr, Roth BJ
    Semin Oncol 1989 Aug;16(4 Suppl 6):110-5
  • Dose-Intensive Chemotherapy in Refractory Germ Cell Cancer--A Phase I/II Trial of High-Dose Carboplatin and Etoposide With Autologous Bone Marrow Transplantation
    Nichols CR, Tricot G, Williams SD, van Besien K, Loehrer PJ, Roth BJ, Akard L, Hoffman R, Goulet R, Wolff SN, et al.
    J Clin Oncol 1989 Jul;7(7):932-9
  • Salvage Therapy in Recurrent Germ Cell Cancer: Ifosfamide and Cisplatin Plus Either Vinblastine or Etoposide
    Loehrer PJ Sr, Lauer R, Roth BJ, Williams SD, Kalasinski LA, Einhorn LH
    Ann Intern Med 1988 Oct 1;109(7):540-6
  • Cisplatin as First-Line Therapy for Metastatic Breast Cancer
    Sledge GW Jr, Loehrer PJ Sr, Roth BJ, Einhorn LH
    J Clin Oncol 1988 Dec;6(12):1811-4
  • Long-Term Complications of Cisplatin-Based Chemotherapy for Testis Cancer
    Roth BJ, Einhorn LH, Greist A
    Semin Oncol 1988 Aug;15(4):345-50
  • Relation of Proliferative Activity to Survival in Patients With Advanced Germ Cell Cancer
    Sledge GW Jr, Eble JN, Roth BJ, Wuhrman BP, Fineberg N, Einhorn LH
    Cancer Res 1988 Jul 1;48(13):3864-8
  • Cisplatin-Based Combination Chemotherapy for Disseminated Germ Cell Tumors: Long-Term Follow-Up
    Roth BJ, Greist A, Kubilis PS, Williams SD, Einhorn LH
    J Clin Oncol 1988 Aug;6(8):1239-47
  • Analysis of Phorbol Ester Stimulated Human Megakaryocyte Development
    Roth BJ, Sledge GW Jr, Straneva JE, Brandt J, Goheen M, Hoffman R
    Blood 1988 Jul;72(1):202-7
  • Flow Cytometry Derived DNA Content of the Primary Lesions of Advanced Germ Cell Tumours
    Sledge GW Jr, Eble JN, Roth BJ, Wuhrman BP, Einhorn LH
    Int J Androl 1987 Feb;10(1):115-20
  • Initial Characterization of a Human Megakaryocytic Leukemia Cell Line, EST-IU
    Sledge GW Jr, Roth BJ, Heerema NA, Glant M, Jansen J, Goheen M, Hoffman R
    Prog Clin Biol Res 1986;215:329-33
  • Establishment in Long Term Culture of Megakaryocytic Leukemia Cells (EST-IU) From the Marrow of a Patient With Leukemia and a Mediastinal Germ Cell Neoplasm
    Sledge GW Jr, Glant M, Jansen J, Heerema NA, Roth BJ, Goheen M, Hoffman R
    Cancer Res 1986 Apr;46(4 Pt 2):2155-9
  • A Study of Optimal Length of Flexible Fiberoptic Sigmoidoscopes for Initial Endoscopic Training
    Lehman GA, Hawes R, Roth B, Hast J
    Dis Colon Rectum 1986 Dec;29(12):878-81
  • Physicians' Estimates of the Probability of Myocardial Infarction in Emergency Room Patients With Chest Pain
    Tierney WM, Fitzgerald J, McHenry R, Roth BJ, Psaty B, Stump DL, Anderson FK
    Med Decis Making 1986 Jan-Mar;6(1):12-7
  • Testicular Cancer: New Directions in Therapy
    Roth B, Loehrer P
    Current Concepts in Oncology 1985;7:(1)
  • Prototype Studies of a Forty-Five Cm Flexible Sigmoidoscope
    Lehman G, Roth B, Hildebrand W
    Indiana Family Practice Residency Journal 1985 Sep;3:(1)11-12
  • Predictors of Myocardial Infarction in Emergency Room Patients
    Tierney WM, Roth BJ, Psaty B, McHenry R, Fitzgerald J, Stump DL, Anderson FK, Ryder KW, McDonald CJ, Smith DM
    Crit Care Med 1985 Jul;13(7):526-31